HMGA1 Modulates Gene Transcription Sustaining a Tumor Signalling Pathway Acting on the Epigenetic Status of Triple-Negative Breast Cancer Cells

Cancers
Carlotta PenzoRiccardo Sgarra

Abstract

Chromatin accessibility plays a critical factor in regulating gene expression in cancer cells. Several factors, including the High Mobility Group A (HMGA) family members, are known to participate directly in chromatin relaxation and transcriptional activation. The HMGA1 oncogene encodes an architectural chromatin transcription factor that alters DNA structure and interacts with transcription factors favouring their landing onto transcription regulatory sequences. Here, we provide evidence of an additional mechanism exploited by HMGA1 to modulate transcription. We demonstrate that, in a triple-negative breast cancer cellular model, HMGA1 sustains the action of epigenetic modifiers and in particular it positively influences both histone H3S10 phosphorylation by ribosomal protein S6 kinase alpha-3 (RSK2) and histone H2BK5 acetylation by CREB-binding protein (CBP). HMGA1, RSK2, and CBP control the expression of a set of genes involved in tumor progression and epithelial to mesenchymal transition. These results suggest that HMGA1 has an effect on the epigenetic status of cancer cells and that it could be exploited as a responsiveness predictor for epigenetic therapies in triple-negative breast cancers.

References

Jul 11, 1998·The Journal of Biological Chemistry·M F FavataJ M Trzaskos
Feb 3, 2000·Proceedings of the National Academy of Sciences of the United States of America·G M PaoI M Verma
May 12, 2000·The Journal of Biological Chemistry·S P ZhongZ Dong
Jul 13, 2000·Molecular and Cellular Biology·L J WoodL M Resar
Aug 11, 2001·Science·T Jenuwein, C D Allis
Sep 21, 2001·Molecular and Cellular Biology·K MerienneP Sassone-Corsi
Nov 7, 2002·Cell·Theodora AgaliotiDimitris Thanos
Oct 9, 2003·The EMBO Journal·Nick GilbertWendy A Bickmore
Nov 13, 2003·Molecular and Cellular Biology·Maofu FuRichard G Pestell
Dec 24, 2003·Molecular Cell·Antoine H F M PetersThomas Jenuwein
Jun 24, 2004·Journal of Cell Science·Monika HarrerRobert Hock
Sep 11, 2004·FEBS Letters·Riccardo SgarraVincenzo Giancotti
Mar 10, 2005·The Journal of Biological Chemistry·Yvonne KumaAna Cuenda
Mar 31, 2005·Proteomics·Riccardo SgarraGuidalberto Manfioletti
Mar 17, 2006·Cancer Research·Francesco FrascaGuidalberto Manfioletti
May 2, 2006·Molecular and Cellular Biology·Michael A ParraJohn J Wyrick
Jun 13, 2006·Cancer Cell·Monica FedeleAlfredo Fusco
Oct 17, 2006·The Biochemical Journal·Gopal P SapkotaDario R Alessi
Aug 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Michael C LawrenceMelanie H Cobb
Oct 14, 2008·Proteomics·Riccardo SgarraGuidalberto Manfioletti

❮ Previous
Next ❯

Datasets Mentioned

BETA
MDA-MB-231
MDA-MB-157

Methods Mentioned

BETA
acetylation
Histone acetylation
co-immunoprecipitation
xenograft
Assay
electrophoresis

Software Mentioned

Elements
NIS
Rad CFX Manager
Bio

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.